Xin Lang Cai Jing·2025-08-14 07:54Core Viewpoint - The article discusses the performance and business operations of Haiprime, a leading multinational pharmaceutical company in China, highlighting its revenue structure, market position, and recent financial results. Company Overview - Haiprime was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development and commercialization [2][7] - The company aims to provide high-quality, safe, and effective medications and services to global patients [2] Financial Performance - For the first quarter of 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7] - As of March 31, 2025, the overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3] Revenue Composition - The revenue composition of Haiprime includes: - Formulations: 56.55% - Heparin sodium and low molecular weight heparin raw materials: 20.25% - CDMO: 19.58% - Others: 3.63% [7] Market Activity - On August 14, Haiprime's stock fell by 1.42%, with a trading volume of 92.2413 million yuan and a turnover rate of 0.55%, resulting in a total market capitalization of 19.383 billion yuan [1] - The stock's average trading cost is 11.38 yuan, with current price levels between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6] Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period, with the average circulating shares per person remaining at zero [7][8] - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]